Compare Marathon Digital Holdings Inc (MARA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Neurocrine Biosciences Inc — how do they compare? Marathon Digital Holdings Inc trades at $9.91 (market cap $3.74B), while Neurocrine Biosciences Inc trades at $157.49 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.4× Marathon Digital Holdings Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MARA | NBIX | |
|---|---|---|
Market Cap | $3.74B | $16.46B |
Sector | Technology | Health |
52-Week High | $22.84 | $185.50 |
52-Week Low | $6.73 | $123.10 |
Enterprise Value | $5.78B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA Holdings trades at $10.09, down 5.26% amid a bearish technical signal and recent earnings misses. The stock faces fundamental pressure with a net income margin of -429.71% for 2026 and negative cash flow from operations. Despite this, analyst consensus remains optimistic with a $16.08 price target, and the company is pivoting its power infrastructure toward AI compute to complement Bitcoin mining.
The outlook is mixed; the high analyst buy rating and strategic pivot offer potential upside, but persistent losses, negative cash flow, and Bitcoin market volatility pose significant risks. Investor sentiment is cautious following Q2 2026 results, with the stock trading well below its 52-week high, highlighting both opportunity and substantial downside exposure.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
